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Rev Bras Psiquiatr. 2007;29(4):301-2 unexplained symptoms, functional disorders, cancer, transplantation, cardiology, endocrinology, neurology, pain management, AIDS, obstetrics-gynecology, pulmonary, renal and GI diseases. In each of these areas, first generation studies identified the frequency of psychiatric morbidity associated with the most common diseases or hospitalization itself. More sophisticated second generation cross-sectional epidemiological studies established the prevalence rates of a broader range of psychiatric disorders in the earlier studied illnesses, as well as less common, or newly recognized disease states. Early empirical efforts to treat psychopathology in the medically ill have been followed by sophisticated intervention trials focused on psychiatric illness (most often depression) in patients with chronic medical illnesses, with the aims including measurement of psychiatric and medical outcomes, as well as quality of life.
An ambitious research agenda for PM lies ahead. The highest priority should be given to studies of major psychiatric disorders in medical illnesses of high public health impact (e.g.: heart disease, diabetes). Well-designed clinical trials are needed to assess the relative efficacy of treatments in improving medical and psychosocial outcomes. Other vital areas of research include nosology and classification (especially the somatoform and functional disorders); more sophisticated studies of the epidemiology, course, and impact of psychopathology over the course of medical illness; and more investigations of etiology, risk factors, imaging, and genetics.
There are many challenges ahead for PM. Psychiatric intervention has become more difficult during medical hospitalization, as length of stay has fallen, and average medical illness acuity has increased. The diagnostic mix on medical inpatient units has evolved, with more delirium, substance abuse, and psychiatric emergencies. In the U.S., the provision of psychiatric services to the medically ill is hampered by hospital funding cuts, poor reimbursement and separated funding of medical and mental health services by insurers. In addition, there are too few PM psychiatrists to meet the needs. Most PM psychiatrists are on consultation services, rarely found outside teaching hospitals, and their services are reactive and very brief. Optimal care for complex illnesses requires collaborative relationships with primary physicians and access to specialized psychiatrists. Psychiatric liaison, where psychiatrists are integrated members of a specialized care team, is a more advanced model, with greater ability to provide early detection and prevention. However, such models are usually limited to selected services at larger teaching hospitals. There is an overall shortage of PM psychiatrists in the U.S., and they are not evenly distributed, but the expansion of accredited fellowship programs will hopefully help address this shortfall. PM and C-L psychiatrists are in even shorter supply and less well geographically distributed in most other countries.
To achieve ideal collaborative care for comorbid medicalpsychiatric illness will require changes in each nation's healthcare delivery systems. Thus, it is important for PM psychiatrists to develop liaison with other physician groups, medical disease advocacy groups, mental health advocacy groups, and policy makers in government and business. 
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